These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 17550819

  • 1. [Prevention of respiratory syncytial virus bronchiolitis].
    Marchac V.
    Arch Pediatr; 2006 Dec; 13 Suppl 5():S12-7. PubMed ID: 17550819
    [No Abstract] [Full Text] [Related]

  • 2. Timing of bronchiolitis hospitalisations and respiratory syncytial virus immunoprophylaxis in non-metropolitan Western Australia.
    Moore HC, Keil AD, Richmond PC, Lehmann D.
    Med J Aust; 2009 Nov 16; 191(10):574. PubMed ID: 19912095
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Prevention of community-acquired respiratory syncytial virus infections in premature infants: cost-benefit evaluation in the Finistère Department].
    Jacquemot L, Catelin C, Dobrzynski M, de Parscau L, Sizun J.
    Arch Pediatr; 2002 Feb 16; 9(2):219-21. PubMed ID: 11915507
    [No Abstract] [Full Text] [Related]

  • 9. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.
    Fernández P, Trenholme A, Abarca K, Griffin MP, Hultquist M, Harris B, Losonsky GA, Motavizumab Study Group.
    BMC Pediatr; 2010 Jun 03; 10():38. PubMed ID: 20525274
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Re: recommendation for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease.
    Onuzo OC.
    Cardiol Young; 2004 Aug 03; 14(4):466-7; author reply 467-9. PubMed ID: 15680062
    [No Abstract] [Full Text] [Related]

  • 12. Respiratory syncytial virus disease: update on treatment and prevention.
    Krilov LR.
    Expert Rev Anti Infect Ther; 2011 Jan 03; 9(1):27-32. PubMed ID: 21171875
    [Abstract] [Full Text] [Related]

  • 13. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
    Frogel M, Nerwen C, Boron M, Cohen A, VanVeldhuisen P, Harrington M, Groothuis J, Palivizumab Outcomes Registry Group.
    Pediatr Infect Dis J; 2008 Oct 03; 27(10):870-3. PubMed ID: 18776822
    [Abstract] [Full Text] [Related]

  • 14. Palivizumab for preterm infants. Is it worth it?
    Embleton ND, Harkensee C, Mckean MC.
    Arch Dis Child Fetal Neonatal Ed; 2005 Jul 03; 90(4):F286-9. PubMed ID: 16036888
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Polivizumab against respiratory syncytial virus?].
    Brunvand L.
    Tidsskr Nor Laegeforen; 2000 Sep 10; 120(21):2570-2. PubMed ID: 11070999
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.